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Abstract Prolyl endopeptidase (PEP) is widely distributed and
thought to play an important role in the degradation of peptide
hormones and neuropeptides, but its biological role is totally
unknown. In this study, we examined PEP activity in
subpopulations of murine T cells and found that PEP activity
was significantly higher in immature thymocytes than in mature
thymocytes or in peripheral T cells. Stimulation of murine
peripheral T cells time-dependently increased PEP activity.
Although murine T cell hybridomas exhibited high PEP activity,
the PEP activity was fully inhibited by treatment with PEP
inhibitor. The pretreated T cells were found to be resistant to
activation-induced cell death (AICD). Similar results were
obtained in murine thymocytes as well as in activated peripheral
T cells. PEP activity in T cell hybridomas remained unchanged
during AICD. These results suggest that T cells expressing high
PEP activity are susceptible to ACID. ß 2002 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Prolyl endopeptidase (PEP) was found as an oxytocin-in-
activating enzyme in human uterus by Walter et al. [1] in
1971. Since then, it has been found to be ubiquitously distrib-
uted among mammalian tissues and various organisms includ-
ing plants and bacteria [2]. Such a wide distribution suggests
the general importance of this enzyme. PEP is one of several
proteases that are speci¢c for proline [3]. However, unlike
other proline-speci¢c aminopeptidases, carboxypeptidases, or
dipeptidases, PEP generally hydrolyzes the peptide bond with-
in polypeptides of 6 30 amino acids at the C-terminal side of
prolyl residues [4^6]. PEP is shown to be capable of rapidly
degrading proline-containing neuropeptide and hormones,
such as substance P, bradykinin, angiotensin II, and thyrotro-
pin-releasing hormone (TRH) in vitro [7,8], and the enzyme is
presumed to participate in their maturation and degradation.
PEP has also been reported to be involved in DNA synthesis
[9], depression [10], amnesia [11], and the generation of amy-
loid L-protein [12^14]. However, the contribution of this en-
zyme in Alzheimer’s pathology has been controversial, be-
cause a recent study indicated that PEP is not involved in
the formation of amyloid L-protein [15].
PEP gene has been cloned from several sources including
human lymphocytes or a human T cell line MOLT4 and char-
acterized [16,17]. Northern blot analysis revealed that human
thymus and spleen also express PEP [17]. However, the phys-
iological functions of PEP in thymus and spleen are currently
unknown. To de¢ne the role of this enzyme in T cells, we
examined PEP activity in subpopulations of murine T cells
by its ability to hydrolyze a £uorescent substrate and found
that PEP activity of immature thymocytes exhibited signi¢-
cantly higher than that of mature thymocytes or of peripheral
naive T cells. In addition, when murine peripheral T cells were
stimulated, PEP activity was increased in a time-dependent
manner. Upon TCR stimulation with antigen (Ag), resting
T cells are activated to proliferate and produce cytokines.
When the activated T cells are restimulated with Ag through
TCR, those T cells undergo apoptosis, which is termed acti-
vation-induced cell death (AICD). AICD is thought to play
an important role in the deletion of autoreactive T cells in
thymus or in periphery, and the maintenance of immune ho-
meostasis [18,19]. Murine T cell hybridomas have been widely
used for the study of the mechanisms of AICD [20^22], and
we observed that murine T cell hybridomas also showed high
PEP activity. Accordingly, we considered it plausible that T
cells with high PEP activity might be sensitive to AICD. In
this study, we tested this hypothesis in murine T cell hybrid-
omas, thymocytes, and activated peripheral T cells using spe-
ci¢c PEP inhibitors.
2. Materials and methods
2.1. Mice
BALB/c female mice were maintained in our animal facility and
used at new-born, 8 weeks of age.
2.2. Antibodies and reagents
Anti-mouse CD3O mAb (145-2C11) was puri¢ed from ascites £uid
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by protein A a⁄nity chromatography. Anti-CD28 (37.51) was pur-
chased from PharMingen (San Diego, CA, USA). 24-well culture
plates were coated with puri¢ed anti-CD3 antibody and/or anti-
CD28 antibody as described previously [22]. All other chemicals
were purchased from Sigma (St. Louis, MO, USA) unless otherwise
noted.
2.3. Preparation of T cell subpopulations
Thymocytes were prepared from thymus glands of BALB/c mice,
and a part of them was used as unfractionated thymocytes. Double
negative (DN) or double positive (DP) thymocytes were prepared
from thymocytes stained with £uorescein isothiocyanate (FITC)-con-
jugated anti-CD4 (GK1.5; PharMingen) and phycoerythrin (PE)-con-
jugated anti-CD8 (53-6.72; PharMingen) by cell sorting on FACS
Vantage (Becton Dickinson, Mountain View, CA, USA). For prepa-
ration of single positive (SP) thymocytes, thymuses were removed
from mice 48 h after administration with 125 mg/kg hydrocortisone
sodium phosphate, and SP thymocytes were obtained by cell sorting
from thymocytes stained with FITC-conjugated anti-CD4 and PE-
conjugated anti-CD8. Unfractionated thymocytes were washed twice
and then resuspended at 1U107/ml in RPMI 1640 medium (Life Tech-
nologies, Grand Island, NY, USA)/5% heat-inactivated fetal calf se-
rum (FCS) (Hyclone Laboratories, Logan, NY, USA) containing 10%
culture supernatant of antibody J11d. The cells were incubated for 45
min on ice, pelleted by centrifugation, and then resuspended in 5%
guinea pig serum as a source of complement. After an additional
incubation at 37‡C for 45 min, the cells were ¢ltered through nylon
mesh to remove aggregated debris, washed twice, and used as J11d3
thymocytes. After spleen cell suspensions were prepared, contaminat-
ing RBC were removed by treatment with erythrocyte-lysing bu¡er
(0.15 M NH4Cl), and splenic T cells were enriched using nylon wool
columns. T cells of lymph node cells were also enriched using nylon
wool columns.
2.4. Assay for PEP activity
PEP activity was determined as described previously [17]. 2U106
cells were suspended in extraction bu¡er (50 mM Tris^HCl pH 7.2,
1 mM EDTA containing the protease inhibitors (phenylmethylsul-
fonyl £uoride, leupeptin, antipain, and pepstatin A) and repeated
freezing and thawing. The homogenate was centrifuged at 15 ,000
rpm for 30 min, and thereafter the supernatant was collected and
kept at 370‡C before use. PEP activity was assayed in 20 mM sodium
phosphate bu¡er (pH 6.0) containing 0.5 mM EDTA, 0.5 mM suc-
cinyl-Gly-Pro-4-methyl-coumaryl-7-amide (Suc-Gly-Pro-MCA) (Pep-
tide Institute, Osaka, Japan) and 100 Wg of cytosolic extracts in a
total volume of 100 Wl. After incubation for 30 min at 37‡C, the
reactions were terminated by addition of 2 ml of 1 M sodium acetate
bu¡er (pH 4.2), and £uorescence intensity was measured at excitation
and emission wavelengths of 380 and 460 nm, respectively. Increase in
£uorescence was standardized using free 7-amino-4-methyl-coumarin
(AMC) (Peptide Institute). Values are given as release of AMC in
nmol/min/mg protein.
2.5. Cells and culture
Ovalbumin-speci¢c T cell hybridoma N3-6-71 [22] was maintained
in RPMI 1640 medium supplemented with 10% heat-inactivated FCS,
5U1035 M 2-ME, 1 mM sodium pyruvate, 2 mM L-glutamate, 100 U/
ml penicillin and 100 Wg/ml streptomycin. To induce AICD, N3-6-71
cells were seeded into anti-CD3 (100 Wg/well)-coated 24-well culture
plates at a density of 5U105 cells/well. As control of PEP inhibitor,
dimethyl sulfoxide (DMSO) was used at a ¢nal concentration of
0.02% (v/v). In the experiments for evaluation of the in£uence of
PEP inhibitors on T cells, the concentration of FCS was reduced to
1%. Thymocytes were prepared from thymus glands of 8-week-old
BALB/c mice and suspended in RPMI 1640 medium supplemented
with 1% FCS and other supplements. To induce apoptosis in thymo-
cytes, the cells were cultured on 24-well culture plates coated with
anti-CD3 (20 Wg/well) and anti-CD28 (20 Wg/well) at a density of
5U106 cells/well. Splenic T cells and lymph node T cells of 8-week-
old mice were resuspended in RPMI 1640 containing 10% FCS and
other supplements. They were stimulated with Con A (2.5 Wg/ml) for
48 h, washed three times and subsequently cultured with 50 U/ml IL-2
for additional 48 h. For restimulation, the cells were resuspended in
the medium as for thymocytes and cultured on anti-CD3 (20 Wg/well)-
coated 24-well culture plates at a density of 5U106 cells/well.
2.6. Determination of cell viability
2.6.1. Trypan blue dye exclusion assay. N3-6-71 cells were seeded
into anti-CD3-coated plates or into control plates. At 24 h of culture,
the cells were harvested by vigorous pipetting and the cell viability
was determined by the trypan blue dye exclusion test.
2.6.2. Propidium iodide (PI) uptake. Thymocytes or peripheral T
cells were harvested, stained with PI (2 Wg/ml), and then the cell
viability was analyzed by a FACScan. The percentage of hypodiploid
cells represented the percentage of apoptotic cells.
2.7. Assay for caspase-3 or caspase-8 activity
Caspase-3 or caspase-8 activity in cell lysates was measured using
caspase-3 or caspase-8 colorimetric protease assay kit (Medical and
Biological Laboratories, Nagoya, Japan). Brie£y, 2U106 cells were
lysed in 100 Wl extract bu¡er (150 mM NaCl, 50 mM Tris^HCl pH
7.2, 1% NP-40 containing the protease inhibitors), centrifuged at
15 000 rpm for 15 min, and the supernatant was kept at 370‡C.
Cytosolic extracts (100 Wg) were diluted in an equal volume of 2Ure-
action bu¡er containing 10 mM DTT and incubated at 37‡C for 1 h
with 200 WM colorimetric substrate for caspase-3 and caspase-8 being
Ac-DEVD-pNA (Ac-Asp-Glu-Val-Asp-p-nitroanilide) and Ac-IETD-
pNA (Ac-Ile-Glu-Thr-Asp-p-nitroanilide), respectively. Production of
cleaved p-nitroanilide was monitored on a microplate reader at an
absorbance of 410 nm.
3. Results
3.1. Murine immature thymocytes exhibit high PEP activity
We prepared the extracts of subpopulations of T cells from
BALB/c mice and measured their PEP activity using a £uo-
rescent substrate, Suc-Gly-Pro-MCA [23]. DN or DP thymo-
cytes of 8-week-old mice were obtained by cell sorting. Thy-
mocytes from neonatal mice were also used, and FACS
analysis con¢rmed that s 97% T cells were CD4CD8
(data not shown). To obtain DP-depleted thymocytes, thymo-
cytes were killed with J11d antibody and complement. As
previously described [24], the residual populations were SP
(85%) and DN (12%) as determined by FACS analysis (data
not shown). SP thymocytes were obtained by cell sorting from
thymocytes of 8-week-old mice 48 h after administration with
glucocorticoid. Unfractionated thymocytes or peripheral T
cells were obtained from 8-week-old mice. As shown in Fig.
1, DN thymocytes, DP thymocytes, and neonatal thymocytes
Fig. 1. PEP activity in subpopulations of T cells from BALB/c
mice. Whole thymocytes of neonatal mice, unfractionated and frac-
tionated thymocytes of 8-week-old mice, or peripheral T cells of 8-
week-old mice were prepared, and PEP activity in each T cell subset
was determined using a £uorescent substrate, Suc-Gly-Pro-MCA. As
indicated, ZPP was added to the reaction mixture at a concentration
of 1 WM.
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showed high PEP activities, which were completely inhibited
by a speci¢c inhibitor of PEP, N-benzyloxycarbonyl-prolyl-
prolinal (Z-Pro-prolinal, ZPP) [25]. Conversely, PEP activities
in the extracts of mature thymocytes or peripheral T cells, i.e.
splenic T cells or lymph node T cells were rather low, com-
pared with those of immature thymocytes.
3.2. Increased PEP activity during activation of
murine peripheral T cells
To examine PEP activity of peripheral naive T cells during
activation, spleen T cells and lymph node T cells were pre-
pared from 8-week-old BALB/c mice, stimulated with Con A
for 48 h, and subsequently cultured with IL-2 for 48 h. At 24-
h intervals, the cells were harvested and PEP activity in the
cells was assessed by their Suc-Gly-Pro-MCA-hydrolyzing ac-
tivity. As shown in Fig. 2, PEP activity in stimulated T cells
was increased in a time-dependent manner. The activity was
completely inhibited by S17092-1, a highly potent PEP inhib-
itor [26]. We con¢rmed that freshly isolated peripheral T cells
were resistant to AICD, but continuous culture in the pres-
ence of Con A followed by IL-2 rendered them sensitive to
AICD (data not shown).
3.3. Pretreatment of murine T cell hybridomas with
PEP inhibitor results in the resistance to AICD
Murine immature thymocytes are susceptible to AICD
whereas mature thymocytes are resistant to AICD [27^30].
Naive mature T cells at early stages of activation are resistant
to AICD but become sensitive at late stages of activation
[18,19]. These observations led us to assume that murine T
cells with high PEP activity might be susceptible to AICD.
Murine T cell hybridoma N3-6-71 was also found to express
high PEP activity (Fig. 3A). When N3-6-71 cells were treated
with either PEP inhibitor, ZPP or S17092-1, PEP activity was
decreased in a dose-dependent manner (data not shown). A
100 WM concentration of S17092-1 caused a nearly complete
inhibition of PEP activity by 4 h. Similarly, ZPP (150 WM)-
treated T cell hybridomas displayed reduced PEP activity.
Because optimal inhibition of PEP activity was achieved at
150 WM of ZPP or 100 WM of S17092-1, these concentrations
were used in subsequent analyses. Pretreatment of N3-6-71
cells with ZPP or S17092-1 did not modulate the cell surface
expression levels of TCR/CD3 (data not shown). Next, we
examined whether murine T cell hybridomas that were pre-
treated with PEP inhibitor could escape from AICD. After
pretreatment with either inhibitor for 4 h, the cells were stimu-
Fig. 2. Increased PEP activity during activation of murine periph-
eral T cells. Peripheral T cells of 8-week-old BALB/c mice were
stimulated with Con A for 48 h, and subsequently cultured with IL-
2 for an additional 48 h. At indicated period, PEP activity was de-
termined using Suc-Gly-Pro-MCA. As indicated, S17092-1 was
added to the reaction mixture at a concentration of 1 WM.
Fig. 3. Pretreatment of murine T cell hybridomas with PEP inhibi-
tor results in the resistance to AICD. A: PEP activity in T cell hy-
bridomas exposed to PEP inhibitor. After N3-6-71 cells were treated
with 150 WM of ZPP or 100 WM of S17092-1 for indicated periods,
the cells were harvested and PEP activity was determined using Suc-
Gly-Pro-MCA. B: Pretreatment of T cell hybridomas with PEP in-
hibitor blocks AICD. After pretreatment with either PEP inhibitor
or DMSO for 4 h, N3-6-71 cells were seeded into control plates or
into anti-CD3 antibody-coated plates. At 24 h of culture, the cell vi-
ability was determined. C, D: PEP inhibitors suppress activation-in-
duced caspase-8 activity (C) and caspase-3 activity (D) in murine T
cell hybridomas. After pretreatment of N3-6-71 cells with ZPP,
S17092-1, or DMSO for 4 h, the cells were cultured in anti-CD3
antibody-coated plates. At indicated times, caspase-8 or caspase-3
activity was determined using a colorimetric protease assay kit. E:
PEP activity during AICD in T cell hybridomas. After N3-6-71 cells
were cultured in anti-CD3-coated plates for indicated periods, PEP
activity was determined using Suc-Gly-Pro-MCA.
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lated with a higher density of immobilized anti-CD3 antibody
for 24 h. As shown in Fig. 3B, V75% of control T cells were
dead as assessed by trypan blue dye exclusion. By contrast,
AICD was apparently inhibited in N3-6-71 cells pretreated
with ZPP or S17092-1.
Induction of apoptosis via Fas is characterized by cross-
linking of Fas with trimeric Fas ligand (FasL) and recruit-
ment of components of death-inducing signaling complex
(DICS) [31]. Activation of the receptor-proximal caspase-8
in the DICS has been shown to initiate a cascade of active
caspases including caspase-3 [32,33]. To investigate whether
the inhibitory action of ZPP or S17092-1 in AICD might
a¡ect the initiator caspase or downstream e¡ector caspases,
we prepared cytosolic extracts from N3-6-71 cells upon stim-
ulation with anti-CD3 antibody in the presence or absence of
pretreatment with ZPP or S17092-1, and measured the cas-
pase-8 activity and the central executioner caspase-3 activity
in the cytosolic extracts using colorimetric substrates Ac-
IETD-pNA and Ac-DEVD-pNA, respectively. Activation-in-
duced apoptosis in N3-6-71 cells is detected after a period of
6^8 h, as evaluated by DNA cleavage [22]. As shown in Fig.
3C, caspase-8 activity was detected 6 h after activation with
anti-CD3 antibody and increased up to 8 h. Similarly, an
enhanced caspase-3 activity was also detectable at 6 h after
activation (Fig. 3D). The pretreatment with ZPP or S17029-1
that was able to entirely block AICD in N3-6-71 cells inhib-
ited the inducible activities of both caspase-8 and caspase-3.
In addition, we examined whether PEP activity in N3-6-71
cells might be increased during AICD and observed that
PEP activity was unchanged up to 10 h after stimulation
with anti-CD3 antibody (Fig. 3E). The same results were ob-
tained in the experiments using another T cell hybridoma, 2-
45-12 [22] (data not shown).
3.4. Inhibition of AICD in murine thymocytes or in
activated peripheral T cells upon pretreatment with
PEP inhibitor
We examined whether PEP inhibitors also have inhibitory
e¡ects on AICD in immature thymocytes or in activated ma-
ture T cells. When thymocytes of BALB/c mice were treated
with 150 WM ZPP or 100 WM S17092-1 for 2 h, reduced PEP
activity was observed as assessed by Suc-Gly-Pro-MCA cleav-
age (data not shown). These pretreated thymocytes or un-
treated thymocytes were further incubated in immobilized
anti-CD3 and anti-CD28 antibodies for 24 h, and then the
cell viability was evaluated by PI staining (Fig. 4A). Either of
PEP inhibitors showed little or no toxicity when added alone
at the concentrations tested. After stimulation of untreated
thymocytes, V38% dead cells were detectable. In contrast,
thymocytes pretreated with ZPP or S17092-1 decreased cell
death comparable to spontaneous cell death in culture. Pe-
ripheral T cells of BALB/c mice were activated with Con A
for 2 days, followed by culture in the presence of IL-2 for
another 2 days. The cells were treated with ZPP or S17092-1
for 4 h. At this period, PEP activity was reduced to back
ground levels (data not shown). When activated T cells were
further restimulated with immobilized anti-CD3 antibody for
24 h, V60% of T cells was dead (Fig. 4B). In contrast, the T
cells pretreated with ZPP or S17092-1 showed a reduced cell
death. Thus, pretreatment with PEP inhibitor prevented TCR-
mediated apoptosis in thymocytes or in activated peripheral T
cells.
4. Discussion
We investigated PEP activity in subpopulations of murine T
cells and found that PEP activity of immature thymocytes was
V10 times higher than that of mature thymocytes or of pe-
ripheral naive T cells. Dipeptidyl peptidase IV (CD26) is a
serine protease that selectively hydrolyzes a peptide bond on
the carboxyl side of proline when proline is the penultimate
residue from the free amino terminus. This enzyme occurs
preferentially on the surface of CD4 T cells and the amount
of enzyme activity increases with T cell activation [34,35].
S17092-1 is shown to be unable to inhibit dipeptidyl peptidase
IV, aminopeptidase B, and M [26], and we can exclude out the
possibility that the activities of these peptidases might contrib-
ute to the PEP activity we assessed.
Murine T cell hybridomas undergo apoptosis upon activa-
tion with a high density of immobilized anti-CD3 antibody,
and T cell hybridomas also showed high PEP activity. The
PEP activity in T cell hybridoma N3-6-71 was unchanged
during AICD. When N3-6-71 cells, whose PEP activity was
reduced by treatment with speci¢c PEP inhibitor, were ex-
posed to anti-CD3 antibody, the cells were protected from
AICD. In addition, when murine peripheral T cells were acti-
vated with Con A followed by IL-2, PEP activity was in-
creased up to 96 h. Even in murine thymocytes as well as in
activated peripheral T cells, pretreatment with PEP inhibitor
prior to stimulation with anti-CD3 antibody prevented from
AICD. These results suggest that T cells expressing high PEP
Fig. 4. Inhibition of AICD in murine thymocytes or activated pe-
ripheral T cells upon pretreatment with PEP inhibitor. A: Inhibition
of AICD in PEP inhibitor-pretreated thymocytes. Thymocytes of 8-
week-old BALB/c mice were treated with or without 150 WM ZPP,
100 WM S17092-1, or DMSO for 2 h. These thymocytes were then
further incubated for 24 h in the absence or presence of immobi-
lized anti-CD3 and anti-CD28. B: Inhibition of AICD in PEP in-
hibitor-pretreated peripheral T cells. Peripheral T cells of BALB/c
mice were stimulated for 4 days as described in Fig. 2. The cells
were then treated with or without 150 WM ZPP, 100 WM S17092-1,
or DMSO for 4 h. These cells were then further incubated for 24 h
in the absence or presence of immobilized anti-CD3 antibody. A, B:
Percentage of apoptosis was determined by PI staining.
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activity are sensitive to ACID and that PEP activity in T cells
may determine their susceptibility to AICD. In addition, pre-
treatment with PEP inhibitor interfered with inducible activa-
tion of caspase-8, an upstream component of the caspase cas-
cade during AICD, and caspase-3, preventing subsequent
apoptotic cell death. The precise mechanism(s) by which inhi-
bition of PEP activity prevents from AICD in T cells is at
present unclear. It has been shown that T cells produce sub-
stance P, one of the well-characterized PEP substances, upon
TCR/CD3 triggering and then substance P contributes to T
cell proliferation in an autocrine fashion [36,37]. Therefore,
further experiments will be done to determine whether sub-
stance P might be synthesized in T cells upon TCR/CD3 trig-
gering and whether PEP might be responsible for the regula-
tion of metabolism of substance P during AICD.
In summary, PEP activity in immature thymocytes was
higher than in mature thymocytes or in peripheral naive T
cells. These results suggest that PEP activity may be used as
a marker to de¢ne the maturation of T cells. In addition, we
indicated that T cells expressing high PEP activity are sensi-
tive to ACID, suggesting that PEP may contribute to the ap-
optotic response observed during T cell activation.
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